Europe Anti-Obesity Drugs Market Strategies, Top Players, Growth Opportunities, Analysis and Forecast by 2031
Europe Anti-Obesity Drugs Market Size and Forecast (2021 - 2031), Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Prescription Drugs and OTC Drugs), Mechanism of Action (Centrally Acting Drugs, Peripherally Acting Drugs, and Others), Drug Class (GLP-1 Agonist, Lipase Inhibitors, MC4R agonist, and Others), GLP-1 Agonist [Semaglutide, Liraglutide, and Tirzepatide (Zepbound)], Application (Appetite Suppression, Inhibition of Fat Absorption or Digestive Enzymes, Metabolic Enhancement, and Combination), Route of Administration (Oral and Parenteral), and Distribution Channel (Hospital Pharmacies, Online Channel, and Retail Pharmacies)
- Status : Published
- Report Code : TIPRE00041493
- Category : Life Sciences
- No. of Pages : 234
- Available Report Formats :
The Europe Anti-Obesity Drugs Market size is expected to reach US$ 12,324.2 Million by 2031 from US$ 1,437.8 Million in 2024. The market is estimated to record a CAGR of 37.4% from 2025 to 2031.
Executive Summary and Europe Anti-Obesity Drugs Market Analysis:Europe anti-obesity drugs market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The market in Europe is experiencing significant growth due to rising obesity rates and supportive government initiatives. Sedentary lifestyles, unhealthy diets, and an aging population contribute to a growing prevalence of obesity, prompting demand for effective medical interventions. Additionally, the link between obesity and chronic diseases such as type 2 diabetes, cardiovascular issues, and certain cancers has heightened the urgency for treatment. Technological advancements and the development of more effective and safer weight-loss drugs, such as GLP-1 receptor agonists, have also bolstered market expansion. Regulatory approvals and reimbursement policies in countries like Germany, France, and the UK further support access to these treatments. Moreover, increasing investments from pharmaceutical companies and strategic collaborations across the healthcare sector are accelerating innovation and product availability. Public awareness campaigns and changing attitudes toward obesity as a treatable medical condition are also encouraging more individuals to seek pharmacological support for weight management.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Europe Anti-Obesity Drugs Market: Strategic Insights
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- By Type, the Europe Anti-Obesity Drugs Market is segmented into Prescription Drugs and OTC Drugs. Prescription Drugs held the largest share of the market in 2024.
- By Mechanism of Action, the Europe Anti-Obesity Drugs Market is segmented into Centrally Acting Drugs, Peripherally Acting Drugs, and Others. Centrally Acting Drugs held the largest share of the market in 2024.
- By Drug Class, the Europe Anti-Obesity Drugs Market is segmented into GLP-1 Agonist, Lipase Inhibitors, MC4R agonist, and Others. GLP-1 Agonist held the largest share of the market in 2024.
- By GLP-1 Agonist, the Europe Anti-Obesity Drugs Market is segmented into Semaglutide, Liraglutide, and Tirzepatide (Zepbound). Semaglutide held the largest share of the market in 2024.
- By Application, the Europe Anti-Obesity Drugs Market is segmented into Appetite Suppression, Inhibition of Fat Absorption or Digestive Enzymes, Metabolic Enhancement, and Combination. Appetite Suppression held the largest share of the market in 2024.
- By Route of Administration, the Europe Anti-Obesity Drugs Market is segmented into Oral and Parenteral. Oral held the largest share of the market in 2024.
- By Distribution Channel, the Europe Anti-Obesity Drugs Market is segmented into Hospital Pharmacies, Online Channel, and Retail Pharmacies. Hospital Pharmacies held the largest share of the market in 2024.
The growing awareness of obesity and its health risks has greatly increased the demand for effective weight management solutions. Concerns about diseases related to lifestyle have led many to look for medical and pharmaceutical help. This awareness is leading to greater acceptance and use of anti-obesity drugs in treatment plans. Furthermore, media reports and public health campaigns are informing people about options for managing obesity. As a result, the market for anti-obesity drugs is seeing rapid growth around the world. Similarly, growing recognition of obesity as a long-term condition in Europe has raised interest in medical weight-loss treatments. Data published by Obesity Facts in April 2025 showed that a Swedish cohort study found GLP-1 drugs are more often prescribed off-label for obesity, particularly among women (70.1%) and native-born Swedes (65.3%). Only 30.7% had previously used approved anti-obesity medications, indicating a shift toward newer treatments. This shows an increase in awareness and demand for drug-based weight management options in Sweden. The growing awareness of obesity as a serious health condition has significantly increased the demand for effective weight management solutions, particularly drug-based therapies. Public health campaigns, medical endorsements, and pharmaceutical innovations have collectively contributed to greater acceptance and usage of anti-obesity medications. This shift reflects a broader change in consumer behavior and healthcare approaches towards managing obesity with scientific and pharmaceutical support. Consequently, the anti-obesity drugs market is poised for sustained growth, driven by ongoing advancements and rising patient demand.
Europe Anti-Obesity Drugs Market Country InsightsBy country, the Europe Anti-Obesity Drugs Market is segmented into Germany, the United Kingdom, France, Spain, Italy, and the Rest of Europe. Germany held the largest share in 2024.
Germany, with a substantial proportion of its adult population classified as overweight or obese, has recognized obesity as a critical public health issue, prompting increased demand for effective weight management solutions. According to an article titled Germany mulls sugar tax: What are the Benefits published in June 2024, around half of German adults are slightly overweight, and almost one in five are obese. The increasing obese population represents a lucrative opportunity for the anti-obesity drugs market in Germany. According to the World Obesity Atlas 2022, the estimated number of adults with a BMI greater than or equal to 30kg/m2 in Germany for women and men by 2030 is as follows-Obesity is a metabolic dysfunction often associated with many chronic diseases, creating a significant healthcare burden. The economic burden of these conditions, encompassing both direct healthcare costs and productivity losses, has underscored the need for effective interventions. A report by ING Bank highlighted that the healthcare costs and productivity losses associated with obesity significantly exceed the costs of new weight-loss drugs such as Ozempic, indicating a clear economic benefit of these medications in countries such as Germany.
Europe Anti-Obesity Drugs Market Company ProfilesSome of the key players operating in the market include GSK Plc, F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Ltd, Novo Nordisk A/S, Eli Lilly and Co, Sun Pharmaceutical Industries Ltd, VIVUS LLC, Currax Pharmaceuticals LLC., AdvaCare Pharma USA LLC, and Rhythm Pharmaceuticals Inc.
These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.
Europe Anti-Obesity Drugs Market Research MethodologyThe following methodology has been followed for the collection and analysis of data presented in this report:
Secondary Research
The research process begins with comprehensive secondary research, utilizing internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:
Company websites,
annual reports, financial statements, broker analyses, and investor presentationsIndustry trade journals
and other relevant publicationsGovernment documents,
statistical databases, and market reportsNews articles,
press releases, and webcasts specific to companies operating in the market
Note:
All financial data included in the Company Profiles section has been standardized to US$. For companies reporting in other currencies, figures have been converted to US$ using the relevant exchange rates for the corresponding year.Primary Research
The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:
- Validate and refine findings from secondary research
- Enhance the expertise and market understanding of the analysis team
- Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects
Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:
Industry stakeholders:
Vice Presidents, Business Development Managers, Market Intelligence Managers, and National Sales ManagersExternal experts:
Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
4. Anti-Obesity Drugs Market Landscape
4.1 Market Overview
4.2 PEST Analysis
5. Europe Anti-Obesity Drugs Market - Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints:
6. Anti-Obesity Drugs Market - Europe Market Analysis
6.1 Europe Anti-Obesity Drugs Market Revenue (US$ Million), 2024 - 2031
6.2 Europe Anti-Obesity Drugs Market Forecast and Analysis
7. Europe Anti-Obesity Drugs Market Revenue Analysis - by Type
7.1 Prescription Drugs
7.1.1 Overview
7.1.2 Prescription Drugs: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.2 OTC Drugs
7.2.1 Overview
7.2.2 OTC Drugs: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8. Europe Anti-Obesity Drugs Market Revenue Analysis - by Mechanism Of Action
8.1 Centrally Acting Drugs
8.1.1 Overview
8.1.2 Centrally Acting Drugs: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.2 Peripherally Acting Drugs
8.2.1 Overview
8.2.2 Peripherally Acting Drugs: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.3 Others
8.3.1 Overview
8.3.2 Others: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9. Europe Anti-Obesity Drugs Market Revenue Analysis - by Drug Class
9.1 GLP-1 Agonist
9.1.1 Overview
9.1.2 GLP-1 Agonist: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.2 Lipase Inhibitors
9.2.1 Overview
9.2.2 Lipase Inhibitors: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.3 MC4R agonist
9.3.1 Overview
9.3.2 MC4R agonist: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.4 Others
9.4.1 Overview
9.4.2 Others: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10. Europe Anti-Obesity Drugs Market Revenue Analysis - by Glp-1 Agonist
10.1 Semaglutide
10.1.1 Overview
10.1.2 Semaglutide: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.2 Liraglutide
10.2.1 Overview
10.2.2 Liraglutide: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.3 Tirzepatide (Zepbound)
10.3.1 Overview
10.3.2 Tirzepatide (Zepbound): Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11. Europe Anti-Obesity Drugs Market Revenue Analysis - by Application
11.1 Appetite Suppression
11.1.1 Overview
11.1.2 Appetite Suppression: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.2 Inhibition of Fat Absorption or Digestive Enzymes
11.2.1 Overview
11.2.2 Inhibition of Fat Absorption or Digestive Enzymes: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.3 Metabolic Enhancement
11.3.1 Overview
11.3.2 Metabolic Enhancement: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.4 Combination
11.4.1 Overview
11.4.2 Combination: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
12. Europe Anti-Obesity Drugs Market Revenue Analysis - by Route Of Administration
12.1 Oral
12.1.1 Overview
12.1.2 Oral: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
12.2 Parenteral
12.2.1 Overview
12.2.2 Parenteral: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
13. Europe Anti-Obesity Drugs Market Revenue Analysis - by Distribution Channel
13.1 Hospital Pharmacies
13.1.1 Overview
13.1.2 Hospital Pharmacies: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
13.2 Online Channel
13.2.1 Overview
13.2.2 Online Channel: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
13.3 Retail Pharmacies
13.3.1 Overview
13.3.2 Retail Pharmacies: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14. Europe Anti-Obesity Drugs Market - Country Analysis
14.1 Europe
14.1.1 Europe Anti-Obesity Drugs Market Revenue and Forecast and Analysis - by Country
14.1.1.1 Europe Anti-Obesity Drugs Market Revenue and Forecast and Analysis - by Country
14.1.2.2 Germany: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14.1.2.2.1 Germany: Europe Anti-Obesity Drugs Market Share - by Type
14.1.2.2.2 Germany: Europe Anti-Obesity Drugs Market Share - by Mechanism Of Action
14.1.2.2.3 Germany: Europe Anti-Obesity Drugs Market Share - by Drug Class
14.1.2.2.4 Germany: Europe Anti-Obesity Drugs Market Share - by Glp-1 Agonist
14.1.2.2.5 Germany: Europe Anti-Obesity Drugs Market Share - by Application
14.1.2.2.6 Germany: Europe Anti-Obesity Drugs Market Share - by Route Of Administration
14.1.2.2.7 Germany: Europe Anti-Obesity Drugs Market Share - by Distribution Channel
14.2.3.3 United Kingdom: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14.2.3.3.1 United Kingdom: Europe Anti-Obesity Drugs Market Share - by Type
14.2.3.3.2 United Kingdom: Europe Anti-Obesity Drugs Market Share - by Mechanism Of Action
14.2.3.3.3 United Kingdom: Europe Anti-Obesity Drugs Market Share - by Drug Class
14.2.3.3.4 United Kingdom: Europe Anti-Obesity Drugs Market Share - by Glp-1 Agonist
14.2.3.3.5 United Kingdom: Europe Anti-Obesity Drugs Market Share - by Application
14.2.3.3.6 United Kingdom: Europe Anti-Obesity Drugs Market Share - by Route Of Administration
14.2.3.3.7 United Kingdom: Europe Anti-Obesity Drugs Market Share - by Distribution Channel
14.3.4.4 France: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14.3.4.4.1 France: Europe Anti-Obesity Drugs Market Share - by Type
14.3.4.4.2 France: Europe Anti-Obesity Drugs Market Share - by Mechanism Of Action
14.3.4.4.3 France: Europe Anti-Obesity Drugs Market Share - by Drug Class
14.3.4.4.4 France: Europe Anti-Obesity Drugs Market Share - by Glp-1 Agonist
14.3.4.4.5 France: Europe Anti-Obesity Drugs Market Share - by Application
14.3.4.4.6 France: Europe Anti-Obesity Drugs Market Share - by Route Of Administration
14.3.4.4.7 France: Europe Anti-Obesity Drugs Market Share - by Distribution Channel
14.4.5.5 Spain: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14.4.5.5.1 Spain: Europe Anti-Obesity Drugs Market Share - by Type
14.4.5.5.2 Spain: Europe Anti-Obesity Drugs Market Share - by Mechanism Of Action
14.4.5.5.3 Spain: Europe Anti-Obesity Drugs Market Share - by Drug Class
14.4.5.5.4 Spain: Europe Anti-Obesity Drugs Market Share - by Glp-1 Agonist
14.4.5.5.5 Spain: Europe Anti-Obesity Drugs Market Share - by Application
14.4.5.5.6 Spain: Europe Anti-Obesity Drugs Market Share - by Route Of Administration
14.4.5.5.7 Spain: Europe Anti-Obesity Drugs Market Share - by Distribution Channel
14.5.6.6 Italy: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14.5.6.6.1 Italy: Europe Anti-Obesity Drugs Market Share - by Type
14.5.6.6.2 Italy: Europe Anti-Obesity Drugs Market Share - by Mechanism Of Action
14.5.6.6.3 Italy: Europe Anti-Obesity Drugs Market Share - by Drug Class
14.5.6.6.4 Italy: Europe Anti-Obesity Drugs Market Share - by Glp-1 Agonist
14.5.6.6.5 Italy: Europe Anti-Obesity Drugs Market Share - by Application
14.5.6.6.6 Italy: Europe Anti-Obesity Drugs Market Share - by Route Of Administration
14.5.6.6.7 Italy: Europe Anti-Obesity Drugs Market Share - by Distribution Channel
14.6.7.7 Rest of Europe: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14.6.7.7.1 Rest of Europe: Europe Anti-Obesity Drugs Market Share - by Type
14.6.7.7.2 Rest of Europe: Europe Anti-Obesity Drugs Market Share - by Mechanism Of Action
14.6.7.7.3 Rest of Europe: Europe Anti-Obesity Drugs Market Share - by Drug Class
14.6.7.7.4 Rest of Europe: Europe Anti-Obesity Drugs Market Share - by Glp-1 Agonist
14.6.7.7.5 Rest of Europe: Europe Anti-Obesity Drugs Market Share - by Application
14.6.7.7.6 Rest of Europe: Europe Anti-Obesity Drugs Market Share - by Route Of Administration
14.6.7.7.7 Rest of Europe: Europe Anti-Obesity Drugs Market Share - by Distribution Channel
15 Competitive Landscape
15.1 Heat Map Analysis by Key Players
15.2 Company Positioning & Concentration
16 Industry Landscape
16.1 Overview
16.2 New Product Development
16.3 Merger and Acquisition
16.4 Other Strategic Developments
17 COMPANY PROFILES
17.1 GSK Plc
17.1.1 Key Facts
17.1.2 Business Description
17.1.3 Products and Services
17.1.4 Financial Overview
17.1.5 SWOT Analysis
17.1.6 Key Developments
17.2 F. Hoffmann-La Roche Ltd
17.2.1 Key Facts
17.2.2 Business Description
17.2.3 Products and Services
17.2.4 Financial Overview
17.2.5 SWOT Analysis
17.2.6 Key Developments
17.3 Teva Pharmaceutical Industries Ltd
17.3.1 Key Facts
17.3.2 Business Description
17.3.3 Products and Services
17.3.4 Financial Overview
17.3.5 SWOT Analysis
17.3.6 Key Developments
17.4 Novo Nordisk AS
17.4.1 Key Facts
17.4.2 Business Description
17.4.3 Products and Services
17.4.4 Financial Overview
17.4.5 SWOT Analysis
17.4.6 Key Developments
17.5 Eli Lilly and Co
17.5.1 Key Facts
17.5.2 Business Description
17.5.3 Products and Services
17.5.4 Financial Overview
17.5.5 SWOT Analysis
17.5.6 Key Developments
17.6 Sun Pharmaceutical Industries Ltd
17.6.1 Key Facts
17.6.2 Business Description
17.6.3 Products and Services
17.6.4 Financial Overview
17.6.5 SWOT Analysis
17.6.6 Key Developments
17.7 VIVUS LLC
17.7.1 Key Facts
17.7.2 Business Description
17.7.3 Products and Services
17.7.4 Financial Overview
17.7.5 SWOT Analysis
17.7.6 Key Developments
17.8 Currax Pharmaceuticals LLC.
17.8.1 Key Facts
17.8.2 Business Description
17.8.3 Products and Services
17.8.4 Financial Overview
17.8.5 SWOT Analysis
17.8.6 Key Developments
17.9 AdvaCare Pharma USA LLC
17.9.1 Key Facts
17.9.2 Business Description
17.9.3 Products and Services
17.9.4 Financial Overview
17.9.5 SWOT Analysis
17.9.6 Key Developments
17.10 Rhythm Pharmaceuticals Inc
17.10.1 Key Facts
17.10.2 Business Description
17.10.3 Products and Services
17.10.4 Financial Overview
17.10.5 SWOT Analysis
17.10.6 Key Developments
18. Appendix
18.1 About The Insight Partners
List of Tables
Table 1. Europe Anti-Obesity Drugs Market Segmentation
Table 2. List of Vendors
Table 3. Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Table 4. Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 5. Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 6. Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 7. Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by GLP-1 Agonist
Table 8. Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 9. Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 10. Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 11. Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Country
Table 12. Germany: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 13. Germany: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 14. Germany: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 15. Germany: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by GLP-1 Agonist
Table 16. Germany: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 17. Germany: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 18. Germany: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 19. United Kingdom: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 20. United Kingdom: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 21. United Kingdom: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 22. United Kingdom: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by GLP-1 Agonist
Table 23. United Kingdom: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 24. United Kingdom: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 25. United Kingdom: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 26. France: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 27. France: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 28. France: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 29. France: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by GLP-1 Agonist
Table 30. France: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 31. France: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 32. France: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 33. Spain: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 34. Spain: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 35. Spain: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 36. Spain: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by GLP-1 Agonist
Table 37. Spain: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 38. Spain: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 39. Spain: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 40. Italy: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 41. Italy: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 42. Italy: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 43. Italy: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by GLP-1 Agonist
Table 44. Italy: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 45. Italy: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 46. Italy: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 47. Rest of Europe: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 48. Rest of Europe: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 49. Rest of Europe: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 50. Rest of Europe: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by GLP-1 Agonist
Table 51. Rest of Europe: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 52. Rest of Europe: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 53. Rest of Europe: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 54. Heat Map Analysis by Key Players
List of Figures
Figure 1. Europe Anti-Obesity Drugs Market Segmentation - Country
Figure 2. PEST Analysis
Figure 3. Ecosystem: Anti-Obesity Drugs Market
Figure 4. Europe Anti-Obesity Drugs Market - Key Market Dynamics
Figure 5. Impact Analysis of Drivers and Restraints
Figure 6. Europe Anti-Obesity Drugs Market Revenue (US$ Million), 2024 - 2031
Figure 7. Europe Anti-Obesity Drugs Market Share (%) - by Type, 2024 and 2031
Figure 8. Prescription Drugs: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 9. OTC Drugs: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 10. Europe Anti-Obesity Drugs Market Share (%) - by Mechanism Of Action, 2024 and 2031
Figure 11. Centrally Acting Drugs: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 12. Peripherally Acting Drugs: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 13. Others: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 14. Europe Anti-Obesity Drugs Market Share (%) - by Drug Class, 2024 and 2031
Figure 15. GLP-1 Agonist: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 16. Lipase Inhibitors: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 17. MC4R agonist: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 18. Others: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 19. Europe Anti-Obesity Drugs Market Share (%) - by GLP-1 Agonist, 2024 and 2031
Figure 20. Semaglutide: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 21. Liraglutide: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 22. Tirzepatide (Zepbound): Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 23. Europe Anti-Obesity Drugs Market Share (%) - by Application, 2024 and 2031
Figure 24. Appetite Suppression: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 25. Inhibition of Fat Absorption or Digestive Enzymes: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 26. Metabolic Enhancement: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 27. Combination: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 28. Europe Anti-Obesity Drugs Market Share (%) - by Route Of Administration, 2024 and 2031
Figure 29. Oral: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 30. Parenteral: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 31. Europe Anti-Obesity Drugs Market Share (%) - by Distribution Channel, 2024 and 2031
Figure 32. Hospital Pharmacies: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 33. Online Channel: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 34. Retail Pharmacies: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 35. Europe Anti-Obesity Drugs Market Breakdown by Key Countries, 2024 and 2031 (%)
Figure 36. Germany: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 37. United Kingdom: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 38. France: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 39. Spain: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 40. Italy: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 41. Rest of Europe: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 42. Company Positioning & Concentration
Yes! We provide a free sample of the report, which includes Report Scope (Table of Contents), report structure, and selected insights to help you assess the value of the full report. Please click on the "Download Sample" button or contact us to receive your copy.
Absolutely - analyst assistance is part of the package. You can connect with our analyst post-purchase to clarify report insights, methodology or discuss how the findings apply to your business needs.
Once your order is successfully placed, you will receive a confirmation email along with your invoice.
• For published reports: You'll receive access to the report within 4-6 working hours via a secured email sent to your email.
• For upcoming reports: Your order will be recorded as a pre-booking. Our team will share the estimated release date and keep you informed of any updates. As soon as the report is published, it will be delivered to your registered email.
We offer customization options to align the report with your specific objectives. Whether you need deeper insights into a particular region, industry segment, competitor analysis, or data cut, our research team can tailor the report accordingly. Please share your requirements with us, and we'll be happy to provide a customized proposal or scope.
The report is available in either PDF format or as an Excel dataset, depending on the license you choose.
The PDF version provides the full analysis and visuals in a ready-to-read format. The Excel dataset includes all underlying data tables for easy manipulation and further analysis.
Please review the license options at checkout or contact us to confirm which formats are included with your purchase.
Our payment process is fully secure and PCI-DSS compliant.
We use trusted and encrypted payment gateways to ensure that all transactions are protected with industry-standard SSL encryption. Your payment details are never stored on our servers and are handled securely by certified third-party processors.
You can make your purchase with confidence, knowing your personal and financial information is safe with us.
Yes, we do offer special pricing for bulk purchases.
If you're interested in purchasing multiple reports, we're happy to provide a customized bundle offer or volume-based discount tailored to your needs. Please contact our sales team with the list of reports you're considering, and we'll share a personalized quote.
Yes, absolutely.
Our team is available to help you make an informed decision. Whether you have questions about the report's scope, methodology, customization options, or which license suits you best, we're here to assist. Please reach out to us at sales@theinsightpartners.com, and one of our representatives will get in touch promptly.
Yes, a billing invoice will be automatically generated and sent to your registered email upon successful completion of your purchase.
If you need the invoice in a specific format or require additional details (such as company name, GST, or VAT information), feel free to contact us, and we'll be happy to assist.
Yes, certainly.
If you encounter any difficulties accessing or receiving your report, our support team is ready to assist you. Simply reach out to us via email or live chat with your order information, and we'll ensure the issue is resolved quickly so you can access your report without interruption.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Nov 2025
Anesthesia Machines Market
Size and Forecast (2021 - 2034), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Advanced Anesthesia Machines, Basic Anesthesia Machines, and Consumables), Customer (Small Hospitals & Nursing Home, Standalone Hospitals, Tertiary Care Hospitals, and Hospital Chain), End User (Anaesthesiologists, Critical Care Specialists, and Others), and Geography (North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America)
Nov 2025
Hospital at Home Market
Size and Forecast (2021 - 2034), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Component (Equipment & Devices and Software & Services), Service Type (Acute Care at Home, Chronic Disease Management at Home, Post Acute or Transitional Care, Palliative Care and Hospice Care, and Rehabilitation Services), Delivery Mode (Remote Monitoring and Telehealth, In-person Home Visits, and Hybrid Models), Patient Demographic ( Adult Patients and Pediatric Patients), Indication (Cardiovascular Conditions, Respiratory Diseases, Orthopedic and Post-Surgical Recovery, Infectious Diseases, Neurological Rehabilitation, and Others), Care Provider (Hospitals and Health Systems, Home Health Agencies, Primary Care or Physician Groups, and Private HaH Providers), and Geography (North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America)
Nov 2025
MRI-guided Focused Ultrasound Therapy Market
Size and Forecast (2021 - 2034), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Application (Breast Cancer, Prostate Cancer, Liver Cancer, Pancreatic Cancer, Breast Lifting and Aesthetic Application, Nipple and Areola Preservation, Post Surgical Applications, and Others), End User (Healthcare Facilities, Diagnostic Imaging Centers, and Research Centers), and Geography (North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America)
Nov 2025
Drug Delivery Devices Contract Manufacturing Market
Size and Forecast (2021 - 2034), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Device Type (Infusion Devices and Administration Set, Syringes, Inhalers, Autoinjectors, and Pen Injectors), Service Type (Full-device Manufacturing, Sub-assembly and Components, and Materials-specific Services), and Geography (North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America)
Nov 2025
IVD Devices Contract Manufacturing Market
Size and Forecast (2021 - 2034), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Service Type (Full-device Manufacturing, Sub-assembly and Components, and Materials-specific Services), Device Type (IVD consumables, IVD equipment), and Geography (North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America)
Nov 2025
Gene Therapy CDMO Market
Size and Forecast (2021 - 2034), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Service Type (Drug Development and Manufacturing, Testing and Regulatory Services, and Other Service Types), End User (Pharmaceutical Companies, Biopharmaceutical Companies, and Other End Users), and Geography (North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America)
Nov 2025
RT-PCR Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Reagents & Consumables, Instruments, and Software & Services), Application (Research Application, Clinical Application, and Forensic Application), End user (Hospitals and Diagnostic Centers, Pharmaceutical and Biotechnology Companies, Research Laboratories and Academic Institutes, Forensic Laboratories, and Clinical Research Organizations)
Nov 2025
dPCR Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Reagents & Consumables, Instruments, and Software & Services), Application (Research Application, Clinical Application, and Forensic Application), End user (Hospitals and Diagnostic Centers, Pharmaceutical and Biotechnology Companies, Research Laboratories and Academic Institutes, Forensic Laboratories, and Clinical Research Organizations)
Get Free Sample For